Equities analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to report ($1.08) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Odonate Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.14) and the highest estimate coming in at ($1.01). Odonate Therapeutics reported earnings of ($1.17) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.7%. The business is expected to issue its next earnings report on Friday, February 28th.
On average, analysts expect that Odonate Therapeutics will report full year earnings of ($4.23) per share for the current fiscal year, with EPS estimates ranging from ($4.30) to ($4.16). For the next year, analysts expect that the firm will post earnings of ($4.73) per share, with EPS estimates ranging from ($5.21) to ($4.25). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Odonate Therapeutics.
Several equities analysts have issued reports on the company. ValuEngine lowered Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research lowered Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday.
ODT traded up $0.97 during trading on Tuesday, hitting $33.10. The company’s stock had a trading volume of 98,400 shares, compared to its average volume of 91,828. Odonate Therapeutics has a twelve month low of $11.54 and a twelve month high of $43.75. The stock’s fifty day moving average price is $29.10 and its 200-day moving average price is $29.57. The firm has a market capitalization of $1.03 billion, a P/E ratio of -9.09 and a beta of 1.83.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Featured Story: Understanding the two types of arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.